Dataset Information


A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice.

ABSTRACT: Fibroblast activation protein (FAP) is highly expressed in the tumor-associated fibroblasts (TAFs) of most human epithelial cancers. FAP plays a critical role in tumorigenesis and cancer progression, which makes it a promising target for novel anticancer therapy. However, mere abrogation of FAP enzymatic activity by small molecules is not very effective in inhibiting tumor growth. In this study, we have evaluated a novel immune-based approach to specifically deplete FAP-expressing TAFs in a mouse 4T1 metastatic breast cancer model. Depletion of FAP-positive stromal cells by FAP-targeting immunotoxin ?FAP-PE38 altered levels of various growth factors, cytokines, chemokines and matrix metalloproteinases, decreased the recruitment of tumor-infiltrating immune cells in the tumor microenvironment and suppressed tumor growth. In addition, combined treatment with ?FAP-PE38 and paclitaxel potently inhibited tumor growth in vivo. Our findings highlight the potential use of immunotoxin ?FAP-PE38 to deplete FAP-expressing TAFs and thus provide a rationale for the use of this immunotoxin in cancer therapy.


PROVIDER: S-EPMC4715643 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC4824564 | BioStudies
2017-01-01 | S-EPMC5514929 | BioStudies
2019-01-01 | S-EPMC6410866 | BioStudies
2015-01-01 | S-EPMC4357278 | BioStudies
2014-01-01 | S-EPMC4182334 | BioStudies
2010-01-01 | S-EPMC7394282 | BioStudies
2010-01-01 | S-EPMC2823984 | BioStudies
2018-01-01 | S-EPMC5893756 | BioStudies
2018-01-01 | S-EPMC6286775 | BioStudies
2011-01-01 | S-EPMC3177016 | BioStudies